PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

fluocinonide Side Effects

The reactions most often reported to the FDA for fluocinonide (also sold as Lidex, Vanos), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

5,460
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of fluocinonide come from 5,460 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 5,460 reports to the FDA Adverse Event Reporting System (FAERS) for fluocinonide (Lidex): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

5,460

Reports Mentioning Death

255

4.7% of reports — not proof the medicine caused the death

Hospitalizations

1,006

18.4% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

PSORIASIS
544
RASH
440
PRURITUS
406
FATIGUE
281
DIARRHOEA
280
NAUSEA
277
PAIN
271
HEADACHE
255
ARTHRALGIA
209
DERMATITIS ATOPIC
173
ERYTHEMA
169
DYSPNOEA
168
DIZZINESS
167
CHRONIC KIDNEY DISEASE
161
CONDITION AGGRAVATED
160
SKIN EXFOLIATION
160

Who Reports Side Effects

Gender Distribution

Female 3,063 (60%)
Male 2,027 (40%)
Unknown 16

Age Distribution

0-17 166 (5%)
18-44 619 (20%)
45-64 1,196 (39%)
65-74 659 (21%)
75+ 466 (15%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 255 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 127
CHRONIC KIDNEY DISEASE 25
ACUTE KIDNEY INJURY 21
RENAL FAILURE 19
END STAGE RENAL DISEASE 16
HYPOTENSION 15
MYOCARDIAL INFARCTION 15
SEPSIS 15
DYSPNOEA 14
ASTHENIA 12
CARDIAC ARREST 11
PNEUMONIA 11
RESPIRATORY FAILURE 11
FATIGUE 10
DISEASE PROGRESSION 9
NEPHROGENIC ANAEMIA 9
PAIN 9
DIARRHOEA 8
NAUSEA 8

Reactions in Hospitalization Reports

Top reactions in 1,006 reports where hospitalization was an outcome.

Reaction Reports
PNEUMONIA 91
DYSPNOEA 89
PAIN 87
FATIGUE 74
NAUSEA 70
DIARRHOEA 69
RASH 65
VOMITING 59
PYREXIA 56
DIZZINESS 55
FALL 55
ANXIETY 52
ASTHENIA 51
ACUTE KIDNEY INJURY 50
HEADACHE 49
HYPERTENSION 46
MALAISE 46
RENAL FAILURE 45
URINARY TRACT INFECTION 44
COUGH 43

Compare fluocinonide vs adapalene →

What the FAERS Data Reveals About fluocinonide Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 5,460 voluntary reports linked to fluocinonide and its brand equivalents (Lidex, Vanos), spanning 2004 through 2025. Of those, 255 (4.7%) listed death as an outcome and 1,006 (18.4%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 60% were female and 40% male; age distribution skews toward 45-64, with 1,196 reports in that bracket. The single most reported reaction is psoriasis with 544 submissions, followed by rash and pruritus.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.